Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (201-210 of 516) with videos related to

Pageof 52
Sort By:
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Leukemia|April 22, 2026
Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myelomaArwa Bohra, Surendra Dasari, Saurabh Zanwar, et al.
British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 20, 2025
Proteomic determinants of renal organ response in light-chain amyloidosisMatthew J Rees, Eli Muchtar, Suheil-Albert Atallah-Yunes, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 15, 2022
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working groupAshutosh D Wechalekar, M Teresa Cibeira, Simon D Gibbs, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 23, 2025
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature ReviewShaji Kumar, Xavier Leleu, Katja C Weisel, et al.
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
Blood Cancer Journal|January 5, 2019
Molecular signatures of multiple myeloma progression through single cell RNA-SeqJin Sung Jang, Ying Li, Amit Kumar Mitra, et al.
Mayo Clinic Proceedings|May 7, 2020
Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo ClinicAishwarya Ravindran, Kandace A Lackore, Amy E Glasgow, et al.
Pageof 52

Showing results (201-210 of 516) with videos related to

Sort By:
Pageof 52
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Leukemia|April 22, 2026
Gene expression-based dissemination score predicts early spread and poor outcomes in multiple myelomaArwa Bohra, Surendra Dasari, Saurabh Zanwar, et al.
British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 20, 2025
Proteomic determinants of renal organ response in light-chain amyloidosisMatthew J Rees, Eli Muchtar, Suheil-Albert Atallah-Yunes, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 15, 2022
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working groupAshutosh D Wechalekar, M Teresa Cibeira, Simon D Gibbs, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 23, 2025
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature ReviewShaji Kumar, Xavier Leleu, Katja C Weisel, et al.
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
Blood Cancer Journal|January 5, 2019
Molecular signatures of multiple myeloma progression through single cell RNA-SeqJin Sung Jang, Ying Li, Amit Kumar Mitra, et al.
Mayo Clinic Proceedings|May 7, 2020
Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo ClinicAishwarya Ravindran, Kandace A Lackore, Amy E Glasgow, et al.
Pageof 52